Corbus Pharmaceuticals Holdings, Inc. filings document a clinical-stage biotechnology issuer focused on oncology and obesity. The record includes Form 8-K material-event reports for clinical and regulatory disclosures involving CRB-701 and CRB-913, Regulation FD corporate presentations and risk language tied to product development, trial timelines and business strategy.
Proxy and governance filings cover board matters, executive compensation, equity awards, employment agreements and officer or director changes. The filings also provide formal disclosure categories for operating and financial results and the governance framework supporting the company’s drug-development pipeline.
Corbus Pharmaceuticals Holdings, Inc. Chief Financial Officer Sean F. Moran reported an open-market sale of 4,701 shares of common stock at a weighted average price of $7.783 per share. After this sale, he directly holds 96,694 shares, including 68,795 unvested restricted stock units.
The transaction was executed under a pre-arranged Rule 10b5-1 trading plan and was used to cover tax withholding obligations arising from the vesting and settlement of RSUs. The sale was mandated by the company’s “sell to cover” election and is described as non-discretionary for the executive.
Corbus Pharmaceuticals Holdings, Inc. director and Chief Executive Officer Yuval Cohen reported an open-market sale of 13,871 shares of common stock at a weighted average price of $7.7826 per share on February 13, 2026.
According to the disclosure, this sale was executed under a Rule 10b5-1 trading plan adopted on March 14, 2025 and was mandated as a “sell to cover” transaction to satisfy tax withholding obligations tied to the vesting and settlement of restricted stock units (RSUs), rather than a discretionary trade. Following this transaction, Cohen directly owned 174,316 shares, which includes 138,049 unvested RSUs subject to their existing vesting schedules.
A holder of Corbus Pharmaceuticals Holdings (symbol CRBP) common stock has filed a notice of proposed sale under Rule 144. The filing covers 20,000 shares of common stock, to be sold through Stifel Nicolaus & Company on the Nasdaq, with an aggregate market value of $812,600. These shares were acquired on February 13, 2026 as restricted stock units granted by the issuer as equity compensation, and became payable on the same date. The notice also confirms the seller states they are not aware of any undisclosed material adverse information about the issuer’s current or future operations.
Octagon Capital Advisors LP, Octagon Investments Master Fund LP, and Ting Jia report a 5.4% beneficial ownership stake in Corbus Pharmaceuticals Holdings, Inc. common stock, representing 955,000 shares. The shares are held by Octagon Investments Master Fund, with Octagon as investment manager and Jia as control person.
The reporting persons share voting and dispositive power over all 955,000 shares and certify that the position was acquired and is held in the ordinary course of business, not for the purpose of changing or influencing control of Corbus Pharmaceuticals.
Corbus Pharmaceuticals’ Chief Medical Officer Dominic Smethurst sold 3,285 shares of common stock on February 3, 2026 at a weighted average price of $8.0898 per share. The shares were sold to cover tax withholding triggered by the vesting and settlement of restricted stock units under an issuer-mandated “sell to cover” arrangement, so the sale was not discretionary. After this transaction, he beneficially owns 95,887 shares, including 86,265 unvested RSUs that remain subject to their vesting schedules.
Corbus Pharmaceuticals Holdings, Inc. Chief Operating Officer Ian Hodgson reported a mandated sale of common stock. On February 3, 2026, he sold 2,415 shares of Corbus common stock at a weighted average price of $8.0899 per share to cover tax withholding from vesting restricted stock units (RSUs).
The company required this "sell to cover" transaction for tax obligations, so it was not a discretionary trade by Hodgson. After the sale, he beneficially owned 51,927 shares, which includes 48,108 unvested RSUs that remain subject to their respective vesting schedules.
Corbus Pharmaceuticals Holdings, Inc.'s Chief Medical Officer, Dominic Smethurst, reported equity awards received on January 14, 2026. He was granted 28,365 restricted stock units (RSUs) that will settle in common shares, with 25% vesting on each of the first four anniversaries beginning January 14, 2027, and a pro rata acceleration feature if his service is terminated by the company without cause after the first vesting date. He also received an annual stock option award for 85,095 shares at an exercise price of $8.26 per share, vesting 25% on January 14, 2027 and the remaining 75% in equal monthly installments over 36 months starting February 14, 2027. Following these transactions, he beneficially owned 99,172 shares of common stock, including 93,065 unvested RSUs subject to their existing vesting schedules.
Corbus Pharmaceuticals Holdings, Inc. reported an equity compensation grant to its Chief Financial Officer, Sean F. Moran. On January 14, 2026, he received 28,082 restricted stock units (RSUs) that will settle in common stock. These RSUs vest 25% on each of the first four anniversaries beginning January 14, 2027, with a pro rata acceleration feature if the company terminates his service without cause after the first vesting date. Following this grant, he beneficially owns 101,395 shares of common stock, including 85,714 unvested RSUs.
On the same date, he was also granted stock options to purchase 84,247 shares of common stock at an exercise price of $8.26 per share, expiring January 14, 2036. Under the company’s 2024 Equity Compensation Plan, 25% of this option vests on January 14, 2027, with the remaining 75% vesting in equal monthly installments over 36 months starting February 14, 2027.
Corbus Pharmaceuticals Holdings, Inc. CEO Yuval Cohen reported new equity awards. On January 14, 2026, he received 50,000 restricted stock units that will settle in common shares, with 25% vesting on each of the first four anniversaries beginning January 14, 2027. Following this grant, he beneficially owned 188,187 common shares, including 173,561 unvested RSUs subject to their vesting schedules. He was also granted stock options for 150,000 shares at an exercise price of $8.26, expiring January 14, 2036, with 25% vesting on January 14, 2027 and the remaining 75% vesting in equal monthly installments over 36 months starting February 14, 2027.
Corbus Pharmaceuticals Holdings, Inc. reported an equity compensation grant to its Chief Operating Officer, Ian Hodgson. On January 14, 2026, he received 28,365 restricted stock units (RSUs), which will be settled in common shares. These RSUs vest 25% on each of the first four anniversaries beginning January 14, 2027, with a provision for partial accelerated vesting if his service is terminated by the company without cause after the first vesting date.
On the same date, he was also granted 85,095 stock options with a $8.26 exercise price under the 2024 Equity Compensation Plan. Twenty‑five percent of this option vests on January 14, 2027, and the remaining 75% vests in equal monthly installments over 36 months starting February 14, 2027. Following these grants, he beneficially owned 54,342 shares of common stock, which include 53,108 unvested RSUs subject to their respective vesting schedules, and 85,095 options.